United States Vaccines Market Insights Forecasts to 2033

• The Market Size is growing at a CAGR of 7.9% from 2023 to 2033
• The US Vaccines Market Size is Expected to Hold a Significant Share by 2033.

The US Vaccines Market Size is Anticipated to Hold a Significant Share by 2033, growing at a CAGR of 7.9% from 2023 to 2033.

Market Overview

Vaccines are biological preparations intended to provide immunity against specific infectious diseases. They work by stimulating the body's immune system to recognize and combat a pathogen such as a virus or bacteria without causing the disease itself. Vaccines also occur in a variety of forms, including inactivated, live attenuated, subunit, and mRNA vaccines, and are used for preventive and therapeutic purposes. Vaccines are an integral part of the public health strategy in the United States, offering protection against a myriad of infectious diseases such as influenza, measles, hepatitis, and in the current context, COVID-19. The U.S. federal government has a prominent role in vaccine development, distribution, and access through programs like the Vaccines for Children program and the National Vaccine Injury Compensation Program (VICP). Federal funding for vaccine research and public health campaigns, coupled with vaccination mandates in certain sectors, has helped strengthen the vaccine market.

Report Coverage

This research report categorizes the market for the United States vaccines based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States vaccine market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each United States vaccine market sub-segment.

Driving Factors

The United States vaccines market Increasing demand for immunization programs that prevent infectious diseases against growing awareness of vaccine benefits and increasing global travel is amplifying the need for widespread vaccination. Recent advancements in new vaccine technologies, including mRNA vaccines, have further proliferated the market. The COVID-19 pandemic emphasized the significance of vaccines and sped up research, development, and adoption. Increasing incidence of preventable diseases, an aging population, and the ever-present threat of emerging infectious diseases keep the market growing.

Restraining Factors

Factors such as vaccine hesitation, high production costs, and concerns about the safety of vaccines affect the US vaccine market. Moreover, this market might face challenges in terms of regulatory restrictions, supply chain disruptions, and unequal access and distribution regarding vaccines.

Market Segment

The U.S. vaccine market share is classified into type and route of administration.

• The mRNA segment is expected to hold the largest market share through the forecast period.

The US vaccine market is by type into recombinant/conjugate/subunit, inactivated, live attenuated, viral vector, mRNA, and toxoid. Among these, the mRNA segment is expected to hold the largest market share through the forecast period. This is attributed to their proven effectiveness, the rapid pace of development, and also as evident by the successes realized from COVID-19 vaccines Pfizer-BioNTech and Moderna. The mRNA platform has demonstrated significant promise not only for this one treatment of COVID-19 but also for other infectious diseases, including RSV, Zika virus, and influenza, and continued investments are expected to spur its growth.

• The parenteral segment is expected to hold the largest market share through the forecast period.

The US vaccine market is segmented by route of administration into parenteral and oral. Among these, the parenteral segment is expected to hold the largest market share through the forecast period. This is attributed to the most vaccines, including influenza, COVID-19, hepatitis, and many others are given parenterally with injection as their route. Injectable vaccines are among the most popular, most effective, and most trusted injections used by healthcare providers.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States vaccine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GlaxoSmithKline plc.
• Sanofi
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Emergent BioSolutions, Inc.
• Inovio Pharmaceuticals, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts regional and country revenue from 2022 to 2033. Spherical Insights has segmented the United States vaccines market based on the below-mentioned segments:

United States Vaccines Market, By Type

• Recombinant/Conjugate/Subunit
• Inactivated
• Live Attenuated
• Viral Vector
• mRNA
• Toxoid

United States Vaccines Market, By Route of Administration

• Parenteral
• Oral